Literature DB >> 2164513

The in-vitro activity of piperacillin/tazobactam, ciprofloxacin, ceftazidime and imipenem against multiple resistant gram-negative bacteria.

S Mehtar1, Y J Drabu, P H Blakemore.   

Abstract

One hundred and fifty Gram-negative bacterial strains including respiratory pathogens, such as Haemophilus influenzae and Branhamella catarrhalis, and Enterobacteriaceae with known resistance to beta-lactam and other antibiotics were tested in vitro for sensitivity to piperacillin, piperacillin/tazobactam (ratio 8:1), ceftazidime, ciprofloxacin and imipenem. A 16-fold or greater reduction in the MIC90 of piperacillin was achieved by the addition of tazobactam, in the respiratory pathogens, thus bringing them within the susceptible range. Among the Enterobacteriaceae, a 32-fold or greater reduction in the MIC90 was found for Providencia stuartii, Proteus mirabilis and Aeromonas hydrophila. When compared with the other three antimicrobials, the combination was found to be active against fewer species of multiply resistant Enterobacteriaceae, but equally effective against H. influenzae and B. catarrhalis.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2164513     DOI: 10.1093/jac/25.6.915

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  6 in total

1.  Relative efficacy of tazobactam, sulbactam and clavulanic acid in enhancing the potency of ampicillin against clinical isolates of Enterobacteriaceae.

Authors:  M Pfaller; A Barry; P Fuchs; E Gerlach; D Hardy; J McLaughlin
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1993-03       Impact factor: 3.267

2.  Pharmacodynamics of piperacillin alone and in combination with tazobactam against piperacillin-resistant and -susceptible organisms in an in vitro model of infection.

Authors:  A H Strayer; D H Gilbert; P Pivarnik; A A Medeiros; S H Zinner; M N Dudley
Journal:  Antimicrob Agents Chemother       Date:  1994-10       Impact factor: 5.191

Review 3.  The development of beta-lactam antibiotics in response to the evolution of beta-lactamases.

Authors:  S Y Essack
Journal:  Pharm Res       Date:  2001-10       Impact factor: 4.200

4.  Comparison of fixed concentration and fixed ratio options for testing susceptibility of gram-negative bacilli to piperacillin and piperacillin/tazobactam.

Authors:  M A Pfaller; A L Barry; P C Fuchs; E H Gerlach; D J Hardy; J C McLaughlin
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-08       Impact factor: 3.267

Review 5.  Future directions in antimicrobial chemotherapy.

Authors:  R Janknegt
Journal:  Pharm Weekbl Sci       Date:  1992-08-21

Review 6.  Piperacillin/tazobactam. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential.

Authors:  H M Bryson; R N Brogden
Journal:  Drugs       Date:  1994-03       Impact factor: 9.546

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.